Pegfilgrastim is under clinical development by PharmaEssentia and currently in Phase I for Neutropenia. According to GlobalData, Phase I drugs for Neutropenia have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pegfilgrastim’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pegfilgrastim overview
Pegfilgrastim (PEG-GCSF) is under development for the treatment of neutropenia. The drug candidate is developed using PEGylaltion technology by combining PEG polymer (polyethylene glycol) and Granulocyte colony-stimulating factor (GCSF) hormone. It is administered through subcutaneous route.
The drug candidate was under development for the treatment of risk of developing myelosuppression following a radiological or nuclear incident.
PharmaEssentia overview
PharmaEssentia is a biotechnology company. It operates as a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes Ropeginterferon alfa-2b, TCRT, P1101, Anti PD-1 (P1801), PEG-GCSF, PEG-cytokine X, Y, Novel checkpoint Abs. P1101, a new generation PEG-Interferon-alpha-2b which is developed using the PEGylation technology platform. Its pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the bloodstream. PharmaEssentia’s products are used in the therapeutic areas of hematology and oncology. The company operates in Taiwan, Japan, Hong Kong, Korea, Singapore and China. PharmaEssentia is headquartered in Taipei, Taiwan.
For a complete picture of Pegfilgrastim’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
